Last reviewed · How we verify
NCT05300243
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
trial testing HPV integration test in HPV Integration in 1 participant. Status unknown.
1 April 2022
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 7 July 2020 |
| Primary completion | 1 April 2022 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- HPV integration test
Conditions studied
- HPV Integration — all drugs for HPV Integration →
Sponsor
Tongji Hospital
Who can join
Adults 18 to 70, female only, with HPV Integration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Verify or expand the search:
- PubMed search for NCT05300243
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HPV integration test
Trials testing the same drug.
- NCT05570331 — Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women · unknown
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05300243 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 29 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05300243.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing